Antiphospholipid antibodies correlate with stroke severity and outcome in patients with antiphospholipid syndrome

References

• Cervera, R., J. C. Piette, J. Font, et al.; Euro-Phospholipid Project Group. 2002. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis. Rheum. 46: 1019–1027
   PubMed Web of Science ®Google Scholar
• Muscal, E., and R. L. Brey. 2008. Neurologic manifestations of antiphospholipid syndrome: integrating molecular and clinical lessons. Curr. Rheumatol. Rep. 10: 67–73
   PubMedGoogle Scholar
• Ruiz-Irastorza, G., M. Crowther, W. Branch, and M. A. Khamashta. 2010. Antiphospholipid syndrome. Lancet 376: 1498–1509
   PubMed Web of Science ®Google Scholar
• Musial, J. 2012. Antiphospholipid antibodies and thrombosis. Thromb. Res. 129: 345–347
   PubMed Web of Science ®Google Scholar
• Dafer, R. M., J. Biller. 2008. Antiphospholipid syndrome: role of antiphospholipid antibodies in neurology. Hematol. Oncol. Clin. North. Am. 22: 95–105
   PubMed Web of Science ®Google Scholar
• Turiel, M., P. Sarzi-Puttini, R. Peretti, et al. 2005. Thrombotic risk factors in primary antiphospholipid syndrome: a 5-year prospective study. Stroke. 36: 1490–1494
   PubMed Web of Science ®Google Scholar
• Krnic-Barrie, S., C. R. O’Connor, S. W. Looney, et al. 1997. A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis. Arch. Intern. Med. 157: 2101–2108
   PubMedGoogle Scholar
• The APASS investigators. 2004. Antiphhospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. J. Am. Med. Assoc. 291: 576–584
   Web of Science ®Google Scholar
• Ortel, T. L. 2012. Antiphospholipid syndrome: laboratory testing and diagnostic strategies. Am. J. Hematol. 87: S75–S781
   Google Scholar
• Male, C., D. Foulon, H. Hoogendoorn, et al. 2005. Predictive value of persistent versus transient antiphospholipid antibody subtypes for the risk of thrombotic events in pediatric patients with systemic lupus erythematosus. Blood. 106: 4152–4158
   PubMed Web of Science ®Google Scholar
• Ludia, C., P. Domenico, C. Monia, et al. 1998. Antiphospholipid antibodies: a new risk factor for restenosis after percutaneous transluminal coronary angioplasty? Autoimmunity. 27: 141–148
   PubMed Web of Science ®Google Scholar
• Szodoray, P., T. Tarr, J. Tumpek, et al. 2009. Identification of rare anti-phospholipid/protein co-factor autoantibodies in patients with systemic lupus erythematosus. Autoimmunity. 42: 497–506
   PubMed Web of Science ®Google Scholar
• Ruiz-Iraztorza, G., M. Crowther, W. Branch, and M. A. Khamashta. 2010. Antiphospholipid syndrome. Lancet 376: 1498–1509
   PubMed Web of Science ®Google Scholar
• Ruiz-Irastorza, G., and M. A. Khamashta. 2005. Stroke and antiphospholipid syndrome: the treatment debate. Rheumatology. 44: 971–974
   PubMed Web of Science ®Google Scholar
• Levine, S. R., L. Salowich-Palm, K. L. Sawaya, et al. 1997. IgG anticardiolipin antibody titers > 40 GPL and the risk of subsequent thrombo-occlusive events and death. Stroke. 28: 1660–1665
   PubMed Web of Science ®Google Scholar
• The Antiphospholipid Antibodies and Stroke Study Group (APASS). 1997. Anticardiolipin antibodies and the risk of recurrent thrombo-occlusive events and death. Neurology. 48: 91–94
   PubMed Web of Science ®Google Scholar
• Verro, P., S. R. Levine, and G. E. Tietjen. 1998. Cerebrovascular ischemic events with highpositive anticardiolipin antibodies. Stroke. 29: 2245–2253
   PubMed Web of Science ®Google Scholar
• Bogousslavsky, J., G. van Melle, F. Regli. 1988. The Lausanne Stroke Registry: analysis of 1,000 consecutive patients with first stroke. Stroke. 19: 1083–1092
   PubMed Web of Science ®Google Scholar
• Arboix, A., J. Alvarez-Sabin, and L. Soler. 1998. Ad hoc Editorial Committee of the Task Force on Cerebrovascular Diseases of SEN. Stroke: classification and diagnostic criteria. Neurologia. 13: 3–10
   PubMedGoogle Scholar
• Brott, T., H. P. Adams Jr, C. P. Olinger, et al. 1989. Measurements of acute cerebral infarction: aclinical examination scale. Stroke. 20: 864–870
   PubMed Web of Science ®Google Scholar
• Van Swieten, J. C., P. J. Koudstaal., M. C. Visser, et al. 1988. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 19: 604–607
   PubMed Web of Science ®Google Scholar
• Vlagea, A., A. Gil, M. V. Cuesta, et al. 2013. Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential markers of antiphospholipid sindrome. Clin. Appl. Thromb. Hemost. 19: 289–296
   PubMed Web of Science ®Google Scholar
• Miyakis, S., M. D. Lockshin, T. Atsumi, et al. 2006. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 4: 295–306
   PubMed Web of Science ®Google Scholar
• Pengo, V., A. Tripodi, G. Reber, et al. 2009. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J. Thromb. Haemost. 7: 1737–1740
   PubMed Web of Science ®Google Scholar
• Reber, G., and P. Moerloose. 2004. Anti-β2-glycoprotein I antibodies – when and how should they be measured? Thromb. Res. 114: 527–531
   PubMed Web of Science ®Google Scholar
• Detkov, D., A. Gil-Aguado, P. Lavilla, et al. 1999. Do antibodies to β2-glycoprotein 1 contribute to the better characterization of the antiphospholipid syndrome? Lupus. 8: 430–438
   PubMed Web of Science ®Google Scholar
• De Groot, P. G. 2011. Mechanisms of anti-phospholipid antibody formation and action. Thromb. Res. 127: S40–S42
   Google Scholar
• Galli, M., G. Borrelli, E. M. Jacobsen, et al. 2007. Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. Blood. 110: 1178–1183
   PubMed Web of Science ®Google Scholar
• Atsumi, T., O. Amengual, S. Yasuda, et al. 2005. Research around beta 2-glycoprotein I: a major target for antiphospholipid antibodies. Autoimmunity. 38: 377–381
   PubMed Web of Science ®Google Scholar
• Andreoli, L., M. Fredi, C. Nalli, et al. 2013. Antiphospholipid antibodies mediate autoimmunity against dying cells. Autoimmunity. 46: 302–306
   PubMed Web of Science ®Google Scholar
• Urbanus, R.T., B. Siegerink, M. Roest, et al. 2009. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet. Neurol. 8: 998–1005
   PubMed Web of Science ®Google Scholar
• Brey, R. L., C. L. Stallworth, D. L. McGlasson, et al. 2002. Antiphospholipid antibodies and stroke in young women. Stroke. 33: 2396–2400
   PubMed Web of Science ®Google Scholar
• Matsuura, E., Y. Igarashi, M. Fujimoto, et al. 1990. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet. 336: 177–178
   PubMed Web of Science ®Google Scholar
• Galli, M., P. Comfurius, C. Maassen, et al. 1990. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet. 335: 1544–1547
   PubMed Web of Science ®Google Scholar
• Roubey, R. A., R. A. Eisenberg, M. F. Harper, and J. B. Winfield. 1995. Winfield. “Anticardiolipin” autoantibodies recognize beta 2-glycoprotein I in the absence of phospholipid. Importance of Ag density and bivalent binding. J. Immunol. 154: 954–960
   PubMed Web of Science ®Google Scholar
• Ali, H. Y., and Z. A. Abdullah. 2008. Anti-beta(2)-glycoprotein I autoantibody expression as a potential biomarker for strokes in patients with anti-phospholipid syndrome. J. Immunotoxicol. 5: 173–177
   PubMed Web of Science ®Google Scholar
• Bevers, E. M., M. Galli, T. Barbui, et al. 1991. Lupus anticoagulant IgG’s (LA) are not directed to phospholipids only, but to a complex of lipidbound human prothrombin. Thromb. Haemost. 66: 629–632
   PubMed Web of Science ®Google Scholar